Helix BioPharma Corp. Initiates OTCQB Application and Hires U.S. Investor Relations Firm

NEXT STORY
BeiGene Announces Acceptance of a Supplemental New Drug Application in China for Tislelizumab in Urothelial Carcinoma
PREV STORY
U.S. FDA Grants Priority Review for Daratumumab in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

The Endocrinology Drugs Market is expected to grow by USD 24.78 bn during 2020-2024, progressing at a CAGR of 7% during the forecast period

author_avatar
NASDAQ Market News

Nasus Pharma Announces Data Demonstrating Efficacy of TaffiX® Intranasal Antiviral Protection Against SARS-CoV-2

author_avatar
NASDAQ Market News

HOOKIPA Pharma to Report Second Quarter 2021 Financial Results on Thursday, August 12, 2021

author_avatar
NASDAQ Market News